Regeneron Pharmaceuticals, Inc. (LON:0R2M)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 60.47B |
| Revenue (ttm) | 10.60B |
| Net Income (ttm) | 3.41B |
| Shares Out | n/a |
| EPS (ttm) | 30.94 |
| PE Ratio | 17.76 |
| Forward PE | 16.99 |
| Dividend | 2.68 (0.34%) |
| Ex-Dividend Date | Nov 20, 2025 |
| Volume | 687 |
| Average Volume | 1,102 |
| Open | 789.85 |
| Previous Close | 786.74 |
| Day's Range | 777.07 - 790.00 |
| 52-Week Range | 477.01 - 805.00 |
| Beta | n/a |
| RSI | 77.70 |
| Earnings Date | Feb 3, 2026 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]
Financial Performance
In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.
Financial numbers in USD Financial StatementsNews
Stocks making the biggest moves midday: Nvidia, Walmart, Strategy, Regeneron & more
These are the stocks posting the largest moves in midday trading.
Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss
On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.'s (NASDAQ: REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following retin...
Wells Fargo Raises Price Target for REGN to $700 | REGN Stock News
Wells Fargo Raises Price Target for REGN to $700 | REGN Stock News
Stocks to Watch Thursday: Walmart, Nvidia, Exact Sciences, Regeneron
Biggest stock movers Thursday: NVDA, PANW, and more
Nvidia leads tech stock gains with strong AI-driven earnings, while Super Micro and Regeneron rise. Track Thursday’s top market movers.
FDA Approves Regeneron's EYLEA HD For Retinal Vein Occlusion And Monthly Dosing Across Indications
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN), announced that the FDA has approved EYLEA HD for adult patients with macular edema following retinal vein occlusion.
Regeneron (REGN) Gains FDA Approval for Eylea HD Injection
Regeneron (REGN) Gains FDA Approval for Eylea HD Injection
Regeneron gets FDA nod for Eylea in macular edema treatment
FDA Approves Eylea HD Injection from Regeneron (REGN) for Eye Conditions
FDA Approves Eylea HD Injection from Regeneron (REGN) for Eye Conditions
EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period
Upto 90% cut in regn charges from today
Lucknow: The reduction in stamp and registration charges for rent agreements is set to be implemented across the state from Thursday. The proposal to .
REGN Factor-Based Stock Analysis - Benjamin Graham
Below is Validea's guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow, REGN rates highest using our Value Investor model based on the published strat...
Regeneron (REGN) Gains EU Approval for Expanded Use of Libtayo
Regeneron (REGN) Gains EU Approval for Expanded Use of Libtayo
Regeneron gets EU nod for expanded approval of Libtayo
REGN: European Approval for Regeneron's Libtayo in Skin Cancer Treatment
REGN: European Approval for Regeneron's Libtayo in Skin Cancer Treatment
Regeneron Pharmaceuticals: European Commission Expands Existing Indication For Libtayo
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) announced that the European Commission has approved the PD-1 inhibitor Libtayo, or cemiplimab, as an adjuvant treatment for adult patients with cutan...
Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation
Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free survival in CSCC in the adjuvant setting, reducing the risk of...
Ex-Dividend Reminder: CenterPoint Energy, Regeneron Pharmaceuticals and LeMaitre Vascular
Looking at the universe of stocks we cover at Dividend Channel, on 11/20/25, CenterPoint Energy, Inc (Symbol: CNP), Regeneron Pharmaceuticals, Inc. (Symbol: REGN), and LeMaitre Vascular Inc (Symbol: L...
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies London Healthcare Conference 2025 Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Jefferies London Healthcare Conference 2025 November 17, 2025 10:30 AM ESTCompany ParticipantsRyan Crowe - Senior...
Regeneron Pharmaceuticals, Inc. (REGN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Regeneron (REGN) to Showcase Hematology Advances at ASH 2025
Regeneron (REGN) to Showcase Hematology Advances at ASH 2025
Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs
Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a BCMAxCD3 bispecific antibody as a monotherapy in this setti...
Final Trade: LMAT, REGN, BA, TJX
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Final Trade: LMAT, REGN, BA, TJX
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.